<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174420</url>
  </required_header>
  <id_info>
    <org_study_id>AAE-CT-DEU-2009-01</org_study_id>
    <nct_id>NCT01174420</nct_id>
  </id_info>
  <brief_title>Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany</brief_title>
  <official_title>A Prospective Randomized Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeon Astron Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeon Astron Europe B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective randomized study is to investigate the efficacy and safety of
      trabeculectomy with ologen Collagen Matrix versus trabeculectomy using mitomycin C (MMC) in
      patients with medically uncontrolled open angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ologen® Collagen Matrix (CM) is an artificial extracellular matrix (ECM) specifically
      configured to support repair in connective and epithelial ocular tissue. The device is
      constructed so as to minimize random growth of fibroblasts and instead to allow them to grow
      through the pores in the matrix. ologen® CM is a biodegradable scaffold matrix, inducing a
      regenerative non-scarring wound healing process without using anti-fibrotic agents. For
      application in glaucoma filtration surgery, ologen® CM is designed to prevent scar formation
      (subconjunctival and scleral flap scarring is the major risk factor for failure of
      trabeculectomy). After implanting the ologen® CM on top of the scleral flap in the
      subconjunctival space, a functional bleb can be created.

      The aim of the present study is to determine the effectiveness of the ologen® CM and reduce
      wound scarring, thereby increasing success of trabeculectomy without side effects of MMC. A
      means of producing better success rate and reduced complications is the purpose of ologen®
      Collagen Matrix for the aid of glaucoma surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) reduction</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>ologen Collagen Matrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin-C (MMC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of ologen Collagen Matrix in trabeculectomy</intervention_name>
    <description>After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing</description>
    <arm_group_label>ologen Collagen Matrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Use of Mitomycin-C in trabeculectomy</intervention_name>
    <description>After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.</description>
    <arm_group_label>Mitomycin-C (MMC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over

          -  Uncontrolled open-angle glaucoma

          -  Subject is willing to sign informed consent

          -  Subject is able and willing to complete post-operative follow-up requirements

        Exclusion Criteria:

          -  Inflammatory eye diseases

          -  Angle-closure glaucoma

          -  Secondary glaucoma with anatomical malformations of the eye

          -  Subjects having single functional eye

          -  Previous conjunctival surgery

          -  Known allergic reactions to ingredients of ologen Collagen Matrix

          -  Excessive myopia (axial length (AL)&gt; 27 mm or more than -10 diopters)

          -  Previous vitrectomy eye surgery

          -  Subjects do not consent to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Dietlein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Cologne, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Dietlein, MD</last_name>
    <phone>+49-221-478-5862</phone>
    <phone_ext>4300</phone_ext>
    <email>thomas.dietlein@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Dietlein, MD</last_name>
      <phone>+49-221-478-5862</phone>
      <phone_ext>4300</phone_ext>
      <email>thomas.dietlein@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Dietlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Dietlein</name_title>
    <organization>Department of Ophthalmology, University of Cologne, Germany</organization>
  </responsible_party>
  <keyword>ologen</keyword>
  <keyword>Mitomycin-C</keyword>
  <keyword>Collagen Matrix</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>glaucoma</keyword>
  <keyword>filtering surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

